Literature DB >> 21907951

Frequency of recurrence of pericardial tamponade in patients with extended versus nonextended pericardial catheter drainage.

Asim M Rafique1, Nimish Patel, Simon Biner, Shervin Eshaghian, Fernando Mendoza, Bojan Cercek, Robert J Siegel.   

Abstract

Recurrence of pericardial tamponade is relatively common after pericardiocentesis. We evaluated the clinical and procedural predictors of recurrent pericardial tamponade after pericardiocentesis. We included 157 consecutive patients with pericardial tamponade (age 62 ± 18 years, 54% men) who had undergone pericardiocentesis from 2000 to 2007. An intrapericardial catheter was used for prolonged drainage of the pericardial effusion (78% of cases) at the discretion of the operator. The overall recurrence rate 11.8 ± 0.6 months after pericardiocentesis was 20% and the mean interval to recurrence was 1.2 ± 2.1 months. However, patients with extended catheter drainage had a reduced recurrence rate of 12% compared to 52% in patients without extended drainage (p <0.001). In the Cox regression modeling, absence of extended drainage (hazard ratio [HR] 4.1, 95% confidence interval [CI] 1.7 to 10, p = 0.002), incomplete drainage of pericardial effusion (HR 9.7, 95% CI 3.6 to 22.7, p <0.001), loculated effusion (HR 11.1, 95% CI 2.9 to 43, p = 0.001), and malignancy (HR 3.3, 95% CI 1.8 to 10.3, p = 0.037) independently correlated with recurrence at 1 year. In conclusion, extended pericardial drainage after catheter placement is associated with a reduced recurrence of pericardial tamponade after pericardiocentesis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21907951     DOI: 10.1016/j.amjcard.2011.07.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Echocardiographic guidance for diagnostic and therapeutic percutaneous procedures.

Authors:  Cam Tu Nguyen; Eunice Lee; Huai Luo; Robert J Siegel
Journal:  Cardiovasc Diagn Ther       Date:  2011-12

2.  The value of the new scoring system for predicting neoplastic pericarditis in the patients with large pericardial effusion.

Authors:  M Szturmowicz; A Pawlak-Cieślik; A Fijałkowska; J Gątarek; A Skoczylas; M Dybowska; K Błasińska-Przerwa; R Langfort; W Tomkowski
Journal:  Support Care Cancer       Date:  2017-03-03       Impact factor: 3.603

3.  Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison.

Authors:  C Labbé; L Tremblay; Y Lacasse
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

4.  Pericardial effusion requiring surgical intervention after stem cell transplantation: a case series.

Authors:  T M Pfeiffer; S J Rotz; T D Ryan; R Hirsch; M Taylor; R Chima; A Pate; J Hlavaty; M Grimley; K Myers; J El-Bietar; S M Davies; S Jodele; C Dandoy
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

5.  Differential Impact of Constrictive Physiology after Pericardiocentesis in Malignancy Patients with Pericardial Effusion.

Authors:  In-Jeong Cho; Hyuk-Jae Chang; Hyemoon Chung; Sang-Eun Lee; Chi Young Shim; Geu-Ru Hong; Jong-Won Ha; Namsik Chung
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

6.  Effectiveness and outcomes of 2 therapeutic interventions for cardiac tamponade: A retrospective observational study.

Authors:  Hady Zgheib; Cynthia Wakil; Sami Shayya; Rana Bachir; Mazen El Sayed
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

Review 7.  Cardiac Tamponade Caused by Cutibacterium acnes: An Updated and Comprehensive Review of the Literature.

Authors:  Ghina Fakhri; Christelle Tayeh; Ghassan Dbaibo; Omar El Sedawy; Nour Abdul Halim; Fadi Bitar; Mariam Arabi
Journal:  Can J Infect Dis Med Microbiol       Date:  2020-07-14       Impact factor: 2.585

8.  Cardiac tamponade in COVID-19 patients: Management and outcomes.

Authors:  Hazim Hakmi; Amir Sohail; Collin Brathwaite; Beevash Ray; Sunil Abrol
Journal:  J Card Surg       Date:  2020-08-13       Impact factor: 1.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.